ArticleThoracic research and practice2026
Cost Analysis of Tuberculosis Disease in the Case of Tuberculosis Control Dispensary.
Article in Thoracic research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the direct and indirect costs associated with tuberculosis (TB) prevention, control, and treatment activities conducted at a TB control dispensary in Türkiye and to assess the economic burden of TB at the patient level. MATERIAL AND
methodsPatient-level cost data for individuals treated in 2023 with International Classification of Diseases, 10
resultsThe average annual direct cost per patient was $346.39 (9,271.59◊), with prescribed medications constituting the largest component of direct costs. The average annual indirect cost per patient amounted to $1,087.80 (32,013.50◊), mainly driven by productivity losses and time spent in healthcare facilities. Overall, the average annual cost per TB patient was estimated at $1,434.22 (41,285.09◊), with indirect costs accounting for nearly three-quarters of the total economic burden.
conclusionThe findings demonstrate that TB imposes a substantial economic burden on patients, primarily through indirect costs, even when TB-related healthcare services are covered by the social security system. These results underscore the need for TB control strategies that extend beyond medical care and incorporate social protection and economic support mechanisms to reduce productivity losses and financial vulnerability among patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.